2021 Q1 Form 10-Q Financial Statement
#000156459021018845 Filed on April 14, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $6.861M | $7.621M |
| YoY Change | -9.97% | 1.68% |
| Cost Of Revenue | $2.012M | $2.503M |
| YoY Change | -19.61% | 1.5% |
| Gross Profit | $4.848M | $5.118M |
| YoY Change | -5.26% | 1.76% |
| Gross Profit Margin | 70.67% | 67.15% |
| Selling, General & Admin | $3.433M | $3.870M |
| YoY Change | -11.28% | 3.33% |
| % of Gross Profit | 70.81% | 75.62% |
| Research & Development | $6.190K | $5.722K |
| YoY Change | 8.18% | -2.75% |
| % of Gross Profit | 0.13% | 0.11% |
| Depreciation & Amortization | $72.49K | $95.76K |
| YoY Change | -24.3% | -8.69% |
| % of Gross Profit | 1.5% | 1.87% |
| Operating Expenses | $3.440M | $3.876M |
| YoY Change | -11.26% | 3.32% |
| Operating Profit | $1.235M | $1.249M |
| YoY Change | -1.11% | 46.32% |
| Interest Expense | $280.2K | $365.3K |
| YoY Change | -23.29% | -10.23% |
| % of Operating Profit | 22.69% | 29.25% |
| Other Income/Expense, Net | -$282.8K | -$309.7K |
| YoY Change | -8.7% | -34.54% |
| Pretax Income | $952.5K | $939.3K |
| YoY Change | 1.4% | 146.84% |
| Income Tax | $258.9K | $252.4K |
| % Of Pretax Income | 27.18% | 26.87% |
| Net Earnings | $693.6K | $687.0K |
| YoY Change | 0.96% | 149.01% |
| Net Earnings / Revenue | 10.11% | 9.01% |
| Basic Earnings Per Share | $0.09 | $0.09 |
| Diluted Earnings Per Share | $0.08 | $0.08 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 7.571M | 7.541M |
| Diluted Shares Outstanding | 8.199M | 8.128M |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $11.36M | $9.375M |
| YoY Change | 21.22% | 18.9% |
| Cash & Equivalents | $11.28M | $8.416M |
| Short-Term Investments | $85.90K | $959.0K |
| Other Short-Term Assets | $825.4K | $199.1K |
| YoY Change | 314.63% | -2.85% |
| Inventory | $868.3K | $1.103M |
| Prepaid Expenses | $451.7K | |
| Receivables | $5.639M | $5.767M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $18.70M | $16.89M |
| YoY Change | 10.66% | -44.38% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $2.610M | $1.775M |
| YoY Change | 47.06% | 21.17% |
| Goodwill | $1.941M | |
| YoY Change | 0.0% | |
| Intangibles | $1.232M | |
| YoY Change | -6.25% | |
| Long-Term Investments | $308.0K | $308.0K |
| YoY Change | 0.0% | 0.0% |
| Other Assets | $80.15M | $26.06M |
| YoY Change | 207.57% | 126.59% |
| Total Long-Term Assets | $86.57M | $27.84M |
| YoY Change | 211.0% | 114.68% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $18.70M | $16.89M |
| Total Long-Term Assets | $86.57M | $27.84M |
| Total Assets | $105.3M | $44.73M |
| YoY Change | 135.33% | 3.2% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $860.1K | $1.381M |
| YoY Change | -37.73% | 36.7% |
| Accrued Expenses | $3.697M | $2.714M |
| YoY Change | 36.22% | -6.47% |
| Deferred Revenue | $8.610M | |
| YoY Change | 4.15% | |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $3.100M | $3.100M |
| YoY Change | 0.0% | 0.0% |
| Total Short-Term Liabilities | $29.84M | $16.07M |
| YoY Change | 85.72% | 5.18% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $1.086M | $5.106M |
| YoY Change | -78.73% | 258.29% |
| Other Long-Term Liabilities | $76.03M | $34.66M |
| YoY Change | 119.35% | -4.51% |
| Total Long-Term Liabilities | $77.11M | $34.66M |
| YoY Change | 122.48% | -8.12% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $29.84M | $16.07M |
| Total Long-Term Liabilities | $77.11M | $34.66M |
| Total Liabilities | $107.0M | $50.73M |
| YoY Change | 110.84% | -1.64% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$21.76M | |
| YoY Change | -11.05% | |
| Common Stock | $36.32M | |
| YoY Change | 1.46% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | $20.56M | |
| YoY Change | 5.07% | |
| Treasury Stock Shares | $6.094M | $6.094M |
| Shareholders Equity | -$1.695M | -$6.001M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $105.3M | $44.73M |
| YoY Change | 135.33% | 3.2% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $693.6K | $687.0K |
| YoY Change | 0.96% | 149.01% |
| Depreciation, Depletion And Amortization | $72.49K | $95.76K |
| YoY Change | -24.3% | -8.69% |
| Cash From Operating Activities | $2.662M | $2.616M |
| YoY Change | 1.78% | 41.07% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $11.98K | $6.961K |
| YoY Change | 72.07% | -85.82% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$150.0K | |
| YoY Change | ||
| Cash From Investing Activities | -$162.0K | -$6.961K |
| YoY Change | 2226.94% | -85.82% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -1.583M | -734.0K |
| YoY Change | 115.72% | -4.59% |
| NET CHANGE | ||
| Cash From Operating Activities | 2.662M | 2.616M |
| Cash From Investing Activities | -162.0K | -6.961K |
| Cash From Financing Activities | -1.583M | -734.0K |
| Net Change In Cash | 916.7K | 1.875M |
| YoY Change | -51.1% | 81.01% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $2.662M | $2.616M |
| Capital Expenditures | $11.98K | $6.961K |
| Free Cash Flow | $2.650M | $2.609M |
| YoY Change | 1.59% | 44.52% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
500000 | |
| CY2020Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
2781668 | |
| CY2021Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
72489 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2021Q1 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
6860617 | |
| CY2021Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
2012197 | |
| CY2021Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
3433312 | |
| CY2021Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
152394 | |
| CY2020Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-51412 | |
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6190 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5722 | |
| CY2021Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
21263 | |
| CY2020Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
44221 | |
| CY2021Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
5625356 | |
| CY2020Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
6371704 | |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
1235261 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
1249070 | |
| CY2021Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-2576 | |
| CY2020Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
54948 | |
| CY2021Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
25 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
627 | |
| CY2021Q1 | us-gaap |
Interest Expense
InterestExpense
|
280219 | |
| CY2020Q1 | us-gaap |
Interest Expense
InterestExpense
|
365299 | |
| CY2021Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-282770 | |
| CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-309724 | |
| CY2021Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
952491 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
939346 | |
| CY2021Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
258901 | |
| CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
252380 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
693590 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
686966 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.09 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.09 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7570913 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7541113 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.08 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.08 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
8198591 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
8128257 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
693590 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
686966 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
95757 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
84818 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
224258 | |
| CY2021Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
90854 | |
| CY2020Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
152991 | |
| CY2017Q2 | us-gaap |
Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
|
100000 | |
| CY2021Q1 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
19682 | |
| CY2020Q1 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
24481 | |
| CY2021Q1 | ccel |
Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
|
66620 | |
| CY2020Q1 | ccel |
Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
|
66491 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-593114 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-177656 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-100975 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-48588 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-109928 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-70394 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
70028 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-61333 | |
| CY2021Q1 | ccel |
Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
|
98675 | |
| CY2020Q1 | ccel |
Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
|
18210 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-97258 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
12131 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
559087 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
628627 | |
| CY2021Q1 | ccel |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-65504 | |
| CY2020Q1 | ccel |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-66300 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
447380 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
556760 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
2662042 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
2615563 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
11978 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
6961 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
150000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-161978 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-6961 | |
| CY2021Q1 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
1775000 | |
| CY2020Q1 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
775000 | |
| CY2021Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
191622 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
41000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1583378 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-734000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
916686 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
1874602 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
6541037 | |
| CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8415639 | |
| CY2020Q1 | ccel |
Operating Lease Liability And Right Of Use Asset Due To Adoption Of Asc842
OperatingLeaseLiabilityAndRightOfUseAssetDueToAdoptionOfASC842
|
562775 | |
| CY2021Q1 | ccel |
Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
|
780070 | |
| CY2021Q1 | ccel |
Patent Option Agreement Credit To Purchase Of Patents And Licenses
PatentOptionAgreementCreditToPurchaseOfPatentsAndLicenses
|
500000 | |
| CY2021Q1 | ccel |
Liabilities Incurred For The Purchase Of Patents And Licenses
LiabilitiesIncurredForThePurchaseOfPatentsAndLicenses
|
58073486 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
191622 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
|
84818 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-6952851 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
41000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
|
224258 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-6000627 | |
| CY2020Q1 | ccel |
Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
|
23320 | |
| CY2021Q1 | ccel |
Covid19
Covid19
|
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Palatino Linotype;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Note 12 – COVID-19</font></p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (“COVID-19”) outbreak.  The Company faces various risks related to health epidemics, pandemics and similar outbreaks, including the global outbreak of COVID-19. The Company believes it has taken appropriate steps to minimize the risk to our employees and to maintain normal business operations and continues to actively monitor the global outbreak and spread of COVID-19 and continues to take steps to mitigate the potential risks to us posed by its spread and related circumstances and impacts. Due to the change in consumer buying patterns as a result of COVID-19, the Company has experienced a decline in new client sales resulting in a decrease in revenues for the three months ended February 28, 2021 compared to the three months ended February 29, 2020. While the ultimate health and economic impact of COVID-19 remains highly uncertain, we expect that our business operations and results of operations, including our net sales, earnings and cash flows, may continue to be impacted by decreases in new client sales. We cannot predict the timing and speed of the recovery, and any delay in the recovery could significantly impact our future results. </p> | |
| CY2021Q1 | us-gaap |
Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
|
478370 | |
| CY2021Q1 | us-gaap |
Sales Commissions And Fees
SalesCommissionsAndFees
|
13507 | |
| CY2021Q1 | us-gaap |
Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
|
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Palatino Linotype;font-style:normal;text-transform:none;font-variant: normal;">Product Warranty and Cryo-Cell Cares<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Program</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. </p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. The Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</p> | |
| CY2020Q1 | us-gaap |
Sales Commissions And Fees
SalesCommissionsAndFees
|
11535 | |
| CY2021Q1 | ccel |
Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
|
18262 | |
| CY2021Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
3 | |
| CY2021Q1 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
36831740 | |
| CY2021Q1 | ccel |
Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
|
8880930 | |
| CY2021Q1 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P12M | |
| CY2005Q4 | us-gaap |
Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
|
50000 | |
| CY2012Q1 | us-gaap |
Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
|
75000 | |
| CY2020Q4 | us-gaap |
Notes Payable
NotesPayable
|
6008433 | |
| CY2021Q1 | us-gaap |
Notes Payable
NotesPayable
|
4233433 | |
| CY2020Q4 | us-gaap |
Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
|
466141 | |
| CY2021Q1 | ccel |
Impairment Of Contract Assets
ImpairmentOfContractAssets
|
0 | |
| CY2020Q1 | ccel |
Impairment Of Contract Assets
ImpairmentOfContractAssets
|
0 | |
| CY2021Q1 | ccel |
Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
|
18262 | |
| CY2021Q1 | ccel |
Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
|
6033 | |
| CY2021Q1 | ccel |
Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
|
8402508 | |
| CY2021Q1 | ccel |
Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
|
9086476 | |
| CY2020Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
36384360 | |
| CY2021Q1 | ccel |
Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
|
3711251 | |
| CY2021Q1 | ccel |
Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
|
3263871 | |
| CY2021Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
36831740 | |
| CY2020Q4 | us-gaap |
Other Asset Impairment Charges
OtherAssetImpairmentCharges
|
1284238 | |
| CY2021Q1 | us-gaap |
Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
|
0 | |
| CY2021Q1 | us-gaap |
Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
|
0 | |
| CY2020Q1 | us-gaap |
Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
|
0 | |
| CY2021Q1 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
| CY2020Q1 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
| CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
85000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
224000 | |
| CY2021Q1 | us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
-3000 | |
| CY2020Q1 | us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
55000 | |
| CY2021Q1 | ccel |
Number Of Units Anticipated To Be Sold Each Year
NumberOfUnitsAnticipatedToBeSoldEachYear
|
18 | |
| CY2021Q1 | ccel |
Percentage Of Decline In Annual Sales
PercentageOfDeclineInAnnualSales
|
0.03 | |
| CY2005Q4 | ccel |
Payment Warranty
PaymentWarranty
|
50000 | |
| CY2012Q1 | ccel |
Increased Payment Warranty
IncreasedPaymentWarranty
|
75000 | |
| CY2017Q2 | ccel |
Increased Payment Warranty
IncreasedPaymentWarranty
|
100000 | |
| CY2021Q1 | ccel |
Inventory Collection Kits
InventoryCollectionKits
|
38934 | |
| CY2020Q4 | ccel |
Inventory Collection Kits
InventoryCollectionKits
|
33006 | |
| CY2021Q1 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
7718 | |
| CY2020Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
7718 | |
| CY2021Q1 | ccel |
Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
|
11881424 | |
| CY2020Q4 | ccel |
Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
|
11991352 | |
| CY2021Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1554081 | |
| CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1181588 | |
| CY2021Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
17000 | |
| CY2020Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
17000 | |
| CY2021Q1 | us-gaap |
Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
|
548085 | |
| CY2021Q1 | ccel |
Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
|
19682 | |
| CY2020Q1 | ccel |
Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
|
24481 | |
| CY2021Q1 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
47537 | |
| CY2020Q4 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
67219 | |
| CY2021Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
4185896 | |
| CY2020Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
5941214 | |
| CY2021Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
40538 | |
| CY2020Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
109780 | |
| CY2021Q1 | us-gaap |
Interest Expense Long Term Debt
InterestExpenseLongTermDebt
|
60220 | |
| CY2020Q1 | us-gaap |
Interest Expense Long Term Debt
InterestExpenseLongTermDebt
|
134261 | |
| CY2021Q1 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
627678 | |
| CY2020Q1 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
587144 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
1149643 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P3Y29D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
3.64 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
1079983 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
|
3.36 | |
| CY2020Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
93380 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
23720 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
69660 | |
| CY2020Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
4.65 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
|
4.99 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
4.53 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
|
The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2020 and the remaining 1/3 on November 30, 2021. | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
0 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
0 | |
| CY2011Q4 | us-gaap |
Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
|
1000000 | |
| CY2012Q2 | us-gaap |
Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
|
3000000 | |
| CY2015Q2 | us-gaap |
Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
|
6000000 | |
| CY2016Q4 | us-gaap |
Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
|
8000000 | |
| CY2021Q1 | us-gaap |
Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
|
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission | |
| CY2021Q1 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
6093535 | |
| CY2020Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
6093535 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
|
In January 2021, the Company exercised its right to extend a lease for 36 months | |
| CY2021Q1 | ccel |
Lessee Operating Lease Extended Term Of Contract
LesseeOperatingLeaseExtendedTermOfContract
|
P36M | |
| CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
780070 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
780070 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1013768 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
299202 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
214567 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
294336 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
295086 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
295086 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
24590 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
109897 | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y9M18D | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.053 | |
| CY2021Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
71566 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
66300 | |
| CY2020Q2 | us-gaap |
Line Of Credit
LineOfCredit
|
350000 | |
| CY2020Q2 | us-gaap |
Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
|
150000 | |
| CY2020Q4 | us-gaap |
Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
|
150000 |
